← Oncology Approval Tracker

FDA DECISION ·

Libtayo

cemiplimab-rwlc · Regeneron

FDA approvalNew or expanded indicationBasal cell carcinoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Patients with locally advanced basal cell carcinoma after a hedgehog pathway inhibitor, or when that treatment was inappropriate.

LAMPGEN ANALYSIS

Why it matters

The decision brings checkpoint inhibition to locally advanced basal cell carcinoma after or outside use of a hedgehog inhibitor.

What research teams should watch

Capture the prior hedgehog inhibitor or documented reason it was unsuitable and the classification of local disease.

PRIMARY RECORDS

Sources